The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer

Abstract Ovarian cancer is associated with the highest mortality rate among gynaecologic malignancies. There is a need to refine the classification of ovarian cancer and identify novel targets. The mammalian target of rapamycin (mTOR) pathway has a crucial role in the pathogenesis and progression of ovarian cancer. This study aims to investigate the prognostic role of p-mTOR and its major downstream effectors p-4EBP1 (eukaryotic initiation factor 4E-binding protein 1) and p-P70S6K (ribosomal protein S6 kinase) in ovarian cancer. p-mTOR, p-4EBP1 and p-P70S6K protein expression was assessed on 195 consecutive ovarian epithelial cancers and correlated to clinicopathological features and survival. We found that high cytoplasmic expression of p-4EBP1 and p-P70S6K was associated with a serous type carcinoma (p = .005) and an advanced FIGO stage (p = .012), respectively. Univariate outcome analysis showed an inverse association between a high expression of p-4EBP1 expression and overall ovarian cancer survival (OS; p = .005) and progression-free survival (PFS; p = .005). p-P70S6K showed an inverse association with PFS (p = .001). Multivariate analyses indicated that p-4EBP1 was an independent predictor of both OS and PFS (p = .016 and p = .041, respectively). Therefore, we concluded that p-4EBP1 high protein expression is an independent predictor of outcome in ovarian cancer patients. Therefore, it could be used as a potential biomarker for prognostic stratification and treatment decisions. Impact statement What is already known on this subject? The mammalian target of rapamycin (mTOR) pathway has a crucial role in the pathogenesis and progression of ovarian cancer. To-date, very limited knowledge is known about the importance of mTOR major downstream effectors p-4EBP1 (eukaryotic initiation factor 4E-binding protein 1) and p-P70S6K (ribosomal protein S6 kinase) in ovarian cancer. What do the results of this study add? In this study, we have provided further evidence of the adverse prognostic behaviour associated with the positive expression of p-mTOR and its major downstream effectors. Moreover and by performing multivariate analysis, we for the first time have proved that p-4EBP1 is an independent predictor of clinical outcome in ovarian cancer. What are the implications of these findings for clinical practice and/or further research? p-4EBP1 could be used as a potential biomarker for prognostic stratification and treatment decisions in ovarian cancer management.

[1]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[2]  S. Grellscheid,et al.  Molecular mechanisms of mTOR regulation by stress , 2014, Molecular & cellular oncology.

[3]  C. Rommel,et al.  PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.

[4]  Kenneth P. Nephew,et al.  Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.

[5]  N. Park,et al.  Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer. , 2011, Gynecologic oncology.

[6]  Yan Du,et al.  The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray , 2009, Journal of experimental & clinical cancer research : CR.

[7]  M. Ilyas,et al.  C‐terminal Tensin‐like (CTEN) is an oncogene which alters cell motility possibly through repression of E‐cadherin in colorectal cancer , 2009, The Journal of pathology.

[8]  H. Huynh,et al.  Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer , 2007, Molecular Cancer Therapeutics.

[9]  D. Wong,et al.  Dissecting the Akt/Mammalian Target of Rapamycin Signaling Network: Emerging Results from the Head and Neck Cancer Tissue Array Initiative , 2007, Clinical Cancer Research.

[10]  T. Gruenberger,et al.  Activated Mammalian Target of Rapamycin Is an Adverse Prognostic Factor in Patients with Biliary Tract Adenocarcinoma , 2007, Clinical Cancer Research.

[11]  R. Pearson,et al.  Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function , 2007, Growth factors.

[12]  J. Baselga,et al.  4E-Binding Protein 1, A Cell Signaling Hallmark in Breast Cancer that Correlates with Pathologic Grade and Prognosis , 2007, Clinical Cancer Research.

[13]  J. Baselga,et al.  Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer , 2006, Cancer.

[14]  In-Hyun Park,et al.  A Nuclear Transport Signal in Mammalian Target of Rapamycin Is Critical for Its Cytoplasmic Signaling to S6 Kinase 1* , 2006, Journal of Biological Chemistry.

[15]  Chung-Liang Ho,et al.  Characterization of Active Mitogen-Activated Protein Kinase in Ovarian Serous Carcinomas , 2004, Clinical Cancer Research.

[16]  Andrew K Godwin,et al.  AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth , 2004, Oncogene.

[17]  M. Bjornsti,et al.  The tor pathway: a target for cancer therapy , 2004, Nature Reviews Cancer.

[18]  N. Sonenberg,et al.  eIF4E – from translation to transformation , 2004, Oncogene.

[19]  E. Schmidt,et al.  Activated eIF4E-binding Protein Slows G1 Progression and Blocks Transformation by c-myc without Inhibiting Cell Growth* , 2004, Journal of Biological Chemistry.

[20]  E. Pujade-Lauraine,et al.  HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[22]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.